ZIOPHARM to Present at 8th Annual Fortis Bank Biotechnology Conference in London
redorbit.com     Mar 27, 2008            

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today Dr. Jonathan Lewis, Chief Executive Officer, will present at the 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008 at 2:00 p.m. GMT (9:00 a.m. ET) at the Four Seasons Hotel Park Lane in London, United Kingdom. [read full story]                    


View all news articles about*:
Ambulatory Biotechnology Care England Four Greater Health Hotels Kingdom London Medical Oncology Pharmaceuticals Research Seasons United Ziopharm
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

COOH-Terminal Truncated HBV X Protein Plays Key Role in Hepatocarcinogenesis.

biowizard.com     11 mins ago          

Authors' Affiliations: State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University. PURPOSE: X protein (HBx), a product of hepatitis B virus, has been closely associated with the development of...                    

comments

                   

The Oncology Group Announces the 11th Edition of Its Popular Handbook, CANCER MANAGEMENT: A...

prnewswire.com     1 hr ago          

The Oncology Group Announces the 11th Edition of Its Popular Handbook, CANCER MANAGEMENT: A MULTIDISCIPLINARY APPROACH MANHASSET, N.Y., Aug. 21 /PRNewswire/ -- The Oncology Group is pleased to announce the publication of the...                    

comments

                   

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex...

yahoo.com     1 hr ago   14 related          

Thursday August 21, 9:42 am ET Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI' Implements immediate restructuring program, which extends cash runway while focusing on clinical pipeline programs BOTHELL,...                    

comments

Vion Pharmaceuticals signs agreement with Hovon for Phase III cancer trial

pharmaceutical-business-review.com     12 hrs ago   6 related          

Vion Pharmaceuticals has signed an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology to conduct a clinical trial of laromustine with standard remission-induction therapy in patients aged 18-65...                    

comments